ReviewMolecular therapy. Nucleic acids2026
LINE-1 retrotransposons: Multifaceted functions and regulatory mechanisms in health and disease.
Review in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long interspersed nuclear element-1 (LINE-1), a prominent class of retrotransposons, is abundantly distributed throughout mammalian genomes and plays critical roles in development, aging, and disease. In this review, we provide a comprehensive overview of the multifaceted functions of LINE-1, with a focus on its regulatory impact on gene transcription and cellular responses across the DNA, RNA, and protein levels. We highlight recent advances in understanding the transcriptional and epigenetic mechanisms controlling LINE-1 transcription. Furthermore, we explore the current challenges and future opportunities in LINE-1 research, emphasizing its potential as a novel therapeutic target. Continued investigation into LINE-1 biology holds promise for deepening our understanding of human health and disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.